The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Open accessAbstract
BACKGROUND: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugsNeedle syringe programmes (NSP) and opioid substitution therapy (OST) are the primary interventions to reduce hepatitis C (HCV) transmission in people who inject drugs. There is good evidence for the effectiveness of NSP and OST in reducing injecting risk behaviour and increasing evidence for the effectiveness of OST and NSP in reducing HIV acquisition risk, but the evidence on the effectiveness of NSP and OST for preventing HCV acquisition is weak. OBJECTIVES: To assess the effects of needle syringe programmes and opioid substitution therapy, alone or in combination, for preventing acquisition of HCV in people who inject drugs. SEARCH METHODS: We searched the Cochrane Drug and Alcohol Register, CENTRAL, the Cochrane Database of Systematic Reviews (CDSR), the Database of Abstracts of Reviews of Effects (DARE), the Health Technology Assessment Database (HTA), the NHS Economic Evaluation Database (NHSEED), MEDLINE, Embase, PsycINFO, Global Health, CINAHL, and the Web of Science up to 16 November 2015. We updated this search in March 2017, but we have not incorporated these results into the review yet. Where observational studies did not report any outcome measure, we asked authors to provide unpublished data. We searched publications of key international agencies and conference abstracts. We reviewed reference lists of all included articles and topic-related systematic reviews for eligible papers. SELECTION CRITERIA: We included prospective and retrospective cohort studies, cross-sectional surveys, case-control studies and randomised controlled trials that measured exposure to NSP and/or OST against no intervention or a reduced exposure and reported HCV incidence as an outcome in people who inject drugs. We defined interventions as current OST (within previous 6 months), lifetime use of OST and high NSP coverage (regular attendance at an NSP or all injections covered by a new needle/syringe) or low NSP coverage (irregular attendance at an NSP or less than 100% of injections covered by a new needle/syringe) compared with no intervention or reduced exposure. DATA COLLECTION AND ANALYSIS: We followed the standard Cochrane methodological procedures incorporating new methods for classifying risk of bias for observational studies. We described study methods against the following 'Risk of bias' domains: confounding, selection bias, measurement of interventions, departures from intervention, missing data, measurement of outcomes, selection of reported results; and we assigned a judgment (low, moderate, serious, critical, unclear) for each criterion. MAIN RESULTS: =0%). We found low-quality evidence of the impact of combined high coverage of NSP and OST, from three studies involving 3241 participants, resulting in a 74% reduction in the risk of HCV acquisition (RR 0.26 95% CI 0.07 to 0.89). AUTHORS' CONCLUSIONS: OST is associated with a reduction in the risk of HCV acquisition, which is strengthened in studies that assess the combination of OST and NSP. There was greater heterogeneity between studies and weaker evidence for the impact of NSP on HCV acquisition. High NSP coverage was associated with a reduction in the risk of HCV acquisition in studies in Europe.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Zhang, J., & Yu, K. F. (1998) · JAMA · doi:10.1001/jama.280.19.1690 · Cited by 4,138
Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. F., & Bell, B. P. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.05.013 · Cited by 2,572
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., & Wiersma, S. T. (2013) · Hepatology · doi:10.1002/hep.26141 · Cited by 2,515
Global epidemiology and genotype distribution of the hepatitis C virus infection
Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., & Razavi, H. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.027 · Cited by 1,903
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review
Mathers, B. M., Degenhardt, L., Phillips, B., Wiessing, L., Hickman, M., Strathdee, S. A., Wodak, A., Panda, S., Tyndall, M., Toufik, A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61311-2 · Cited by 1,285
Self-citation
Cited by
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
EASL recommendations on treatment of hepatitis C: Final update of the series☆
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.018 · Cited by 1,252
Global patterns of opioid use and dependence: harms to populations, interventions, and future action
Degenhardt, L., Grebely, J., Stone, J., Hickman, M., Vickerman, P., Marshall, B. D. L., Bruneau, J., Altice, F. L., Henderson, G., Rahimi-Movaghar, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32229-9 · Cited by 832
Self-citationPimpin, L., Cortez-Pinto, H., Negro, F., Corbould, E., Lazarus, J. V., Webber, L., & Sheron, N. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.011 · Cited by 710
Strang, J., Volkow, N. D., Degenhardt, L., Hickman, M., Johnson, K., Koob, G. F., Marshall, B. D. L., Tyndall, M., & Walsh, S. L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0137-5 · Cited by 639
Self-citationAccelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
Cooke, G. S., Andrieux-Meyer, I., Applegate, T. L., Atun, R., Burry, J. R., Cheinquer, H., Dusheiko, G., Feld, J. J., Gore, C., Griswold, M. G., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30270-x · Cited by 535
Self-citationThe opioid overdose crisis as a global health challenge
Krausz, R. M., Westenberg, J. N., & Ziafat, K. (2021) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000712 · Cited by 91
“With such high fatality rates worldwide, the overdose crisis has become the biggest public health threat in the developed world since the HIV epidemic.”
BackgroundInfluentialBarbosa, C., Fraser, H., Hoerger, T. J., Leib, A., Havens, J. R., Young, A., Kral, A., Page, K., Evans, J., Zibbell, J., et al. (2019) · Addiction · doi:10.1111/add.14731 · Cited by 48
“, 2017 [25] Relative risk of acquiring HCV while on MAT+SSP Product of relative risk for MAT and SSP DAA SVR rate 85-95% Uniform 85-95% Uniform AASL 2017 [11] Screening and diagnosis costs, 2016 USD Screening with rapid test (negative result) 35 Gamma (15, 2) 28 Gamma (15, 2) Cipriano et al.”
BackgroundMethodInfluentialSelf-citationStone, J., Degenhardt, L., Grebely, J., Larney, S., Altice, F. L., Smyrnov, P., Rahimi-Movaghar, A., Alavi, M., Young, A. M., Havens, J. R., et al. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30538-1 · Cited by 40
Self-citationInjections and infections: understanding syringe service program utilization in a rural state
Thakarar, K., Sankar, N., Murray, K., Lucas, F. L., Burris, D., & Smith, R. P. (2021) · Harm Reduction Journal · doi:10.1186/s12954-021-00524-1 · Cited by 32
Roux, P., Donadille, C., Magen, C., Schatz, E., Stranz, R., Curado, A., Tsiakou, T., Verdes, L., Aleksova, A., Carrieri, P., et al. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2020.102992 · Cited by 18
Lanièce Delaunay, C., Klein, M. B., Godin, A., Cox, J., Kronfli, N., Lebouché, B., Doyle, C., & Maheu-Giroux, M. (2023) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2023.104026 · Cited by 9
Kudrina, I., Puzhko, S., Filion, K. B., Gore, G., Paraskevopoulos, E., Windle, S., Martel, M. O., & Eisenberg, M. J. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01852-w · Cited by 4
Metadata
- Authors
- Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., Jordan, A., Degenhardt, L., Hope, V., Hutchinson, S., Maher, L., Palmateer, N., Taylor, A., Bruneau, J., & Hickman, M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2017-09-18
- Volume
- 2017
- Issue
- 9
- Pages
- CD012021-CD012021
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2754268575
- Cited by
- 305
- References
- 131
- FWCI
- 23.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.